|
Volume 16, Issue 3 (May 2014) 16, 331–333; doi: 10.4103/1008-682X.127813
The metastatic castration-resistant prostate cancer treatment paradigm: more choices, more questions
Evan Y Yu1, William K Oh2
1Department of Medicine, Division of Medical
Oncology, University of Washington, Seattle,
WA 98109, USA; 2Division of Hematology and Medical
Oncology, Tisch Cancer Institute, Icahn School of
Medicine at Mount Sinai, New York, NY 10029, USA.
Correspondence: A/Prof. EY Yu (evanyu@u.washington.edu); and Prof. WK Oh (william.oh@mssm.edu)
published online: 08 April 2014
| Abstract |
|
The world of prostate cancer has dramatically changed in the last few
years. The original paradigm that metastatic castration‑resistant prostate cancer (mCRPC) is untreatable is clearly wrong.
Full Text |
PDF |
中文摘要 |
|
| |
| Browse: 3190 |
|
